IR情報

2022/06/24～2022/11/18

IR情報＆株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2022
11/1815:30 当社子会社(日本革新創薬株式会社)の角膜内皮治療薬の実施権譲渡のお知らせ
11/1815:30 業績予想の修正に関するお知らせ
11/18325335321328-0.91%394,60097億3351万+2.18%
11/17338357323331+3.76%2,276,10098億2254万+3.76%
11/1615:00 緑内障・高眼圧症治療剤「グラアルファ配合点眼液」薬価収載のお知らせ
11/16327328319319-1.54%185,80094億6644万+0.31%
11/15320328317324+0.62%200,10096億1481万+1.89%
11/14308327305322+4.55%359,70095億5546万+1.26%
11/11297313296308+1.65%269,30091億4001万-3.75%
11/1015:30 2022年12月期第3四半期決算短信〔日本基準〕(連結)
11/10307314303303-1.62%191,60089億9163万-5.02%
11/09317317301308-3.14%307,30091億4001万-2.84%
11/08322327318318-1.24%205,40094億3676万+0.63%
11/07331331318322-3.3%501,80095億5546万+3.21%
11/04328338324333-0.3%230,80098億8189万+7.77%
11/02323341315334+3.41%464,80099億1157万+9.51%
11/01330333317323-2.12%415,70095億8514万+7.31%
10/31344353330330-2.94%607,20097億9287万+10.74%
10/28335341325340+1.8%633,400100億8962万+15.65%
10/27316336315334+5.03%580,30099億1157万+15.17%
10/263193283173180%311,20094億3676万+11.19%
10/25313322309318+1.27%190,10094億3676万+12.37%
10/24325326309314-3.38%313,30093億1806万+12.54%
10/21315326315325+3.83%289,20095億6566万+17.75%
10/20325329313313-5.15%384,40092億1246万+15.07%
10/19309335309330+6.11%744,10097億1282万+22.68%
10/18306312301311+0.65%236,30091億5360万+17.36%
10/17301313297309+2.66%290,30090億9473万+17.94%
10/14299308292301+1.69%320,70088億5927万+16.22%
10/13303306292296-3.9%353,80087億1210万+15.63%
10/12309313291308-1.91%789,40090億6530万+21.74%
10/11319332312314-3.98%580,70092億4189万+26.1%
10/07333350311327-8.4%2,888,50096億2452万+33.47%
10/06273357273357+28.88%2,362,800105億750万+48.13%
10/05281284267277+0.73%553,50081億5288万+17.87%
10/0415:00 神経疼痛治療薬「DW-5LBT」今後の見通しについて
10/04261278255275+4.56%495,70080億9402万+18.53%
10/03241264235263+9.58%528,70077億4082万+14.35%
09/30238245235240-1.23%124,50070億6387万+5.26%
09/29226246226243+9.46%461,20071億5217万+7.05%
09/28237237220222-6.72%183,70065億3408万-1.33%
09/27243245228238-0.42%390,10070億500万+5.78%
09/2615:30 緑内障・高眼圧症治療剤「K-232(販売名:グラアルファ配合点眼液)」の国内製造販売承認取得のお知らせ
09/26234239233239+0.84%103,00070億3443万+6.7%
09/22232238231237+0.85%80,00069億7557万+6.28%
09/21237237231235-1.26%65,70069億1670万+5.86%
09/20236238233238+2.15%120,90070億500万+7.69%
09/16238238231233-0.85%61,50068億5784万+5.91%
09/15240241235235+1.29%118,40069億1670万+7.31%
09/14225233225232+1.31%53,10068億2840万+6.42%
09/13236238229229-1.72%73,10067億4011万+5.05%
09/12237241233233-2.1%90,90068億5784万+7.37%
09/09241242230238-0.83%233,30070億500万+9.68%
09/08228247226240+5.73%579,90070億6387万+11.11%
09/07225227220227+1.79%130,90066億8124万+5.58%
09/06217224217223+2.76%136,90065億6351万+3.72%
09/05217218213217+0.46%78,80063億8691万+0.93%
09/02223251216216+0.47%1,126,50063億5748万+0.47%
09/01212215211215+0.94%35,70063億2805万-0.46%
08/31211213211213+0.47%21,00062億6918万-1.39%
08/30212212211212+0.95%13,70062億3975万-1.85%
08/29212213209210-1.41%43,70061億8088万-2.78%
08/2615:30 フックス角膜内皮変性症治療剤「K-321」の米国における第III相臨床試験開始のお知らせ
08/26213214211213-0.47%25,50062億6918万-1.84%
08/252132152112140%17,50062億9861万-1.38%
08/24212218211214+0.47%51,90062億9861万-1.38%
08/23213213211213+0.47%44,50062億6918万-1.84%
08/22213215212212-1.85%30,20062億3975万-2.3%
08/19212217211216+1.41%36,50063億5748万0%
08/18210215209213+1.43%38,90062億6918万-1.39%
08/172102122092100%22,70061億8088万-2.78%
08/16209214209210+0.96%27,60061億8088万-2.78%
08/15214214208208-1.89%60,80061億2202万-3.26%
08/12213218212212-1.4%30,90062億3975万-1.4%
08/10214216208215-1.38%83,70063億2805万0%
08/0915:30 営業外収益及び営業外費用の計上に関するお知らせ
08/0915:30 2022年12月期第2四半期決算説明資料
08/0915:30 2022年12月期第2四半期決算短信〔日本基準〕(連結)
08/09218223217218+1.4%37,00064億1635万+1.4%
08/08222222213215-3.59%65,70063億2805万+0.47%
08/052252262212230%56,60065億6351万+4.21%
08/04220224220223+1.36%21,90065億6351万+4.69%
08/03221221216220-1.35%20,60064億7521万+3.77%
08/02217224216223+1.83%38,10065億6351万+5.19%
08/01225225210219-2.67%57,50064億4578万+3.79%
07/29229229223225-1.32%30,30066億2238万+7.14%
07/28226230220228+1.33%82,30067億1067万+9.09%
07/27218225216225+2.74%55,20066億2238万+8.17%
07/26212219209219+2.82%32,30064億4578万+5.29%
07/25216216209213-1.39%29,70062億6918万+2.9%
07/22216225216216-0.92%131,50063億5748万+4.35%
07/21214218213218+1.87%42,30064億1635万+5.31%
07/20212214211214+0.94%53,30062億9861万+3.88%
07/1915:30 第三者割当による第1回無担保転換社債型新株予約権付社債及び第11回新株予約権の発行に係る払込完了に関するお知らせ
07/19211212209212+1.92%115,00062億3975万+2.91%
07/152092092072080%6,40061億2202万+1.46%
07/14206210206208-0.48%25,70061億2202万+0.97%
07/13213213205209+1.95%46,40061億5145万+1.46%
07/12205206204205-0.49%17,90060億3372万-0.97%
07/11210211204206+1.48%55,60060億6315万-0.48%
07/08204205203203-0.98%38,30059億7485万-2.4%
07/07205205203205+0.49%30,10060億3372万-1.44%
07/062042062032040%30,60060億429万-1.92%
07/05204206204204-0.97%19,50060億429万-1.92%
07/04210210204206-0.96%46,80060億6315万-0.96%
07/01219223204208+2.97%553,00061億2202万0%
06/3015:30 新規パイプライン(再生医療用細胞製品)の共同開発契約に関する説明資料
06/3015:30 角膜内皮障害を対象とした再生医療用細胞製品の共同開発契約の締結及び資本提携並びに資金借入に関するお知らせ
06/3015:30 第三者割当による第1回無担保転換社債型新株予約権付社債及び第11回新株予約権の募集に関するお知らせ
06/30203206202202-1.46%19,60059億4542万-2.88%
06/29202205202205+0.99%37,70060億3372万-1.44%
06/28202204202203+0.5%19,30059億7485万-2.4%
06/27206206202202-1.94%35,60059億4542万-2.88%
06/24206206203206-0.48%44,00060億6315万-0.96%